Follow-up procedures for the SOC clinic group (with and without lottery incentives)
ADVERSE EVENTS, OPPORTUNISTIC INFECTIONS
Participants will initiate ART at the clinic and, if feasible, receive quarterly chart review (either paper charts or through electronic medical records (EMRs) where available) to review safety labs (creatinine at 3, 6, and 12 months after ART initiation, for participants on TDF, and viral load 6 and 12 months after ART initiation), adherence data, ART refills, and engagement in clinical care. A study team member will facilitate linkages of the participant to the study to enable follow-up and chart extraction. Participants will complete a questionnaire on opportunistic infections, engagement in care, adverse events, and, if they have started ART, ART symptoms either by phone or in person at the clinic at months 3, 6, 9, 12, and 15. Participants will receive an 18-month follow-up visit during which they will complete the follow-up questionnaire (month 18 visit detailed below).